Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $100,000.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 5,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the sale, the chief financial officer now owns 73,849 shares in the company, valued at $1,476,980. This represents a 6.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Kory James Wentworth also recently made the following trade(s):

• On Friday, November 29th, Kory James Wentworth sold 1,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.97, for a total transaction of $19,970.00.
• On Monday, November 11th, Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock. The shares were sold at an average price of $19.98, for a total transaction of $172,567.26.
• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Stock Up 1.8 %

Shares of Entrada Therapeutics stock opened at $20.32 on Friday. The stock has a market cap of $760.37 million, a PE ratio of 12.78 and a beta of -0.18. The business has a fifty day simple moving average of $17.98 and a 200-day simple moving average of $16.43. Entrada Therapeutics, Inc. has a 12 month low of $11.35 and a 12 month high of $20.50.

Hedge Funds Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in Entrada Therapeutics by 210.6% in the third quarter. Barclays PLC now owns 45,110 shares of the company’s stock worth $720,000 after purchasing an additional 30,585 shares during the period. Geode Capital Management LLC increased its stake in shares of Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after buying an additional 46,512 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Entrada Therapeutics by 89.1% in the third quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock valued at $260,000 after buying an additional 7,659 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at $634,000. Finally, State Street Corp increased its stake in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Oppenheimer raised their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. HC Wainwright lifted their price objective on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.